Category: Inside BIO Industry Analysis
Setting the Record Straight on Innovation and Drug Development
Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, …
See What’s New at the 2015 BIO Investor Forum
The 2015 BIO Investor Forum is just two weeks away, and it’s gearing up to …
Academics Weigh In on Journal Article: “GMOs, Herbicides, and Public Health”
An article published in the New England Journal of Medicine by biotech critics Philip Landrigan …
Joint U.S.-Brazil Communique Demonstrates Commitment to Collaboration
In June, Brazilian President Dilma Rousseff met with President Barack Obama to reaffirm their commitment …
Congress, Media Focused on Biotech Food Labeling
Media coverage of the biotech food labeling debate is at a fever pitch as the …
The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech
In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent …
State of the Industry for Emerging Therapeutic Companies
Emerging therapeutic companies are at their strongest point in a decade. In our new report …
Maximize Your Savings Potential During BIO International Convention
$161,000,000 That’s how much BIO saved life science companies in aggregate on their 2014 purchases …
13 Days Until BIO 2015: Moneyball: Acing the Big Pharma/Small Biotech Deal
In just a few weeks, thousands of players in the pharma and biotech industry will …
BIO’s Dave Thomas Talks VC Funding with Daniel Levine
Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, …